Givosiran (ALN-AS1) ( DrugBank: Givosiran )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
254	ポルフィリン症	3

254. ポルフィリン症

臨床試験数 : 72 / 薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03338816 (ClinicalTrials.gov)	November 16, 2017	7/11/2017	ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1)in Patients With Acute H ...	ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-labe ...	Acute Hepatic Porphyria;Acute Intermittent Porphyria;Porphyria, Acute Intermittent;Acute Porphyria;H ...	Drug: Givosiran;Drug: Placebo	Alnylam Pharmaceuticals	NULL	Completed	12 Years	N/A	All	94	Phase 3	United States;Australia;Bulgaria;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic o ...
2	NCT02949830 (ClinicalTrials.gov)	October 2016	28/10/2016	A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1)in Patient With Acu ...	A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of ...	Acute Intermittent Porphyria	Drug: givosiran (ALN-AS1)	Alnylam Pharmaceuticals	NULL	Completed	18 Years	N/A	All	16	Phase 1/Phase 2	United States;Sweden;United Kingdom
3	NCT02452372 (ClinicalTrials.gov)	May 6, 2015	19/5/2015	A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)	A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Phar ...	Acute Intermittent Porphyria	Drug: givosiran (ALN-AS1);Drug: Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	NULL	Completed	18 Years	65 Years	All	40	Phase 1	United States;Sweden;United Kingdom

First Previous1Next Last